Published in Immunol Lett on January 12, 2010
Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet (2012) 0.80
Innate Immunity and the Role of Epithelial Barrier During Aspergillus fumigatus Infection. Curr Immunol Rev (2012) 0.77
Complementary Roles of the Classical and Lectin Complement Pathways in the Defense against Aspergillus fumigatus. Front Immunol (2016) 0.76
A Sweet Response to a Sour Situation: The Role of Soluble Pattern Recognition Receptors in the Innate Immune Response to Invasive Aspergillus fumigatus Infections. PLoS Pathog (2016) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Transcript dynamics of proinflammatory genes revealed by sequence analysis of subcellular RNA fractions. Cell (2012) 4.10
Coccidioidomycosis. Clin Infect Dis (2005) 3.88
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
Caspofungin. Clin Infect Dis (2003) 3.03
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54
Coccidioidomycosis. Infect Dis Clin North Am (2003) 2.13
Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One (2013) 1.79
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother (2006) 1.76
Antifungal drug resistance. Clin Infect Dis (2003) 1.65
Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again? J Med Microbiol (2011) 1.52
Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol (2009) 1.49
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis (2003) 1.44
Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology (2002) 1.43
Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36
Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis (2003) 1.33
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2002) 1.22
Development of a murine model of cerebral aspergillosis. J Infect Dis (2002) 1.19
Splicing kinetics and transcript release from the chromatin compartment limit the rate of Lipid A-induced gene expression. RNA (2013) 1.08
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol (2006) 1.06
Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia (2007) 1.05
New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol (2010) 1.02
Animal models: an important tool in mycology. Med Mycol (2007) 1.01
Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J Infect Dis (2002) 1.00
Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun (2004) 1.00
Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother (2008) 0.98
Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrob Agents Chemother (2004) 0.98
Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis (2008) 0.98
Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob Agents Chemother (2012) 0.97
Metallic taste from electrical and chemical stimulation. Chem Senses (2005) 0.97
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis (2007) 0.96
Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother (2006) 0.96
Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother (2004) 0.94
Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother (2006) 0.93
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med Mycol (2011) 0.92
Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother (2012) 0.92
Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis (2003) 0.91
Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J Infect Dis (2006) 0.90
Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother (2005) 0.90
Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine (2009) 0.89
Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 0.89
Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother (2007) 0.88
Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine (2011) 0.88
Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev (2011) 0.87
Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother (2003) 0.87
Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis. Infect Immun (2007) 0.87
Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun (2004) 0.86
A murine model of coccidioidal meningitis. J Infect Dis (2003) 0.86
Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol (2010) 0.86
Demonstration of a novel technique to quantitatively assess inflammatory mediators and cells in rat knee joints. J Inflamm (Lond) (2007) 0.86
Who let the dogs out? Infection control did: utility of dogs in health care settings and infection control aspects. Am J Infect Control (2006) 0.86
Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol (2012) 0.86
Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease. Mycopathologia (2014) 0.85
Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D. Infect Immun (2006) 0.85
Genomic DNA microarray comparison of gene expression patterns in Paracoccidioides brasiliensis mycelia and yeasts in vitro. Microbiology (2009) 0.84
Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect (2004) 0.84
Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother (2005) 0.83
Real-time PCR and quantitative culture for monitoring of experimental Aspergillus fumigatus intracranial infection in neutropenic mice. J Med Microbiol (2011) 0.83
Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. Clin Infect Dis (2011) 0.83
Global population structure of Aspergillus terreus inferred by ISSR typing reveals geographical subclustering. BMC Microbiol (2011) 0.82
Influence of 17β-estradiol on gene expression of Paracoccidioides during mycelia-to-yeast transition. PLoS One (2011) 0.82
Saccharomyces as a vaccine against systemic candidiasis. Immunol Invest (2012) 0.82
Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med Mycol (2006) 0.82
Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area. Mycopathologia (2004) 0.81
Microsatellite multilocus genotyping clarifies the relationship of Candida parapsilosis strains involved in a neonatal intensive care unit outbreak. Diagn Microbiol Infect Dis (2011) 0.81
Molecular epidemiology of the global and temporal diversity of Candida parapsilosis. Scand J Infect Dis (2008) 0.81
Experimental animal models of coccidioidomycosis. Ann N Y Acad Sci (2007) 0.81
Inflammatory marker profiles in an avian experimental model of aspergillosis. Med Mycol (2013) 0.81
Draft genome sequence of the human pathogen Halomonas stevensii S18214T. J Bacteriol (2012) 0.80
Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis (2006) 0.80
Advances against aspergillosis. Clin Infect Dis (2003) 0.80
Coccidioidal meningitis. Clin Infect Dis (2006) 0.80
Protein targets for broad-spectrum mycosis vaccines: quantitative proteomic analysis of Aspergillus and Coccidioides and comparisons with other fungal pathogens. Ann N Y Acad Sci (2012) 0.80
Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2009) 0.79
Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis. Antimicrob Agents Chemother (2013) 0.78
Aspergillus fumigatus invasion increases with progressive airway ischemia. PLoS One (2013) 0.78
DNA binding compounds targeting fungal pathogens: an emerging concept in the discovery of novel antifungal agents. Curr Opin Investig Drugs (2002) 0.78
Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus. Med Mycol (2010) 0.78
Mycologic catastrophe. Antimicrob Agents Chemother (2013) 0.78
Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos). Med Mycol (2010) 0.78
Susceptibility to pulmonary blastomycosis in young compared to adult mice: immune deficiencies in young mice. Med Mycol (2006) 0.78